Shopping Cart
Remove All
Your shopping cart is currently empty
"ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1]."
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | "ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1]." |
| In vivo | Administered orally at 150 mg/kg/day and 300 mg/kg/day starting 48 hours post-MCT treatment for 21 to 26 days, ET receptor antagonist 3 (compound 17d) significantly reduced mean pulmonary arterial pressure (mPAP) in MCT-exposed rats, decreased levels of HIF1α, ANP, and TNNI3, exhibited antioxidant activity, and inhibited lipid peroxidation [1]. |
| Molecular Weight | 548.61 |
| Formula | C27H28N6O5S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.